Fellowship Application Guidelines

Fellowships from NCC are established at $40,000 per annum for post-doctoral awards, and are awarded annually. Fellowships are intended for applicants under age 35 with less than two years of post- doctoral laboratory experience, except in extenuating circumstances. Fellowships are also limited to applicants having received no more than one prior fellowship or one career development award. Individuals receiving concurrent support from another organization are not eligible to apply.

Preference will be given to studies that have direct relevance to the diagnosis and treatment of human cancer.

Fellowship awards are not necessarily restricted to salary. Depending on the circumstances, part of the funds may be used for supplies or other valid expenses, which should be listed in the proposed budget. NCC reserves the right to delete any item it deems inappropriate.

The fellowship may be transferable upon application and review, in the event that the fellow leaves the sponsoring organization.

Fellowships generally are extended for a second year. However, adequate progress must have been demonstrated during the first year as evidenced through a progress report submitted with renewal application. Awards are limited to one per laboratory. There can be several different applications if they are on different topics. However, only one award could be made per lab in any round of applications.

NCC fellowship grants do not include funds for institutional overhead and a statement by the institution accepting this condition is required.


2019 New and Renewed Research Grants


2019 Grants


Total Grand Funding To Date

National Cancer Center 2019/2020 Grants

The following post-doc fellowship grants and renewals were approved for 2019/2020

Polina Vaitsenfeld, Ph.D.

The Rockefeller University, NY, NY

PROJECT: Enhancing antibody-mediated immunity against tumor-associated carbohydrate antigens
“Characterizing the mechanism of action of antibodies targeting the tumor-associated carbohydrate sialyl Lewis A, followed by antibody engineering for maximizing the therapeutic effect in vivo.”

Darko Barisic, Ph.D.

Weill Medical College of Cornell Univ

PROJECT: Role of chromatin remodeling complex BAF in lymphomagenesis
40% of lymphoma patients relapse highlighting inefficiency of current treatments. Chromatin remodelers are highly mutated in lymphoma, and this project aims to decipher the biological role of chromatin remodelers in the initiation, propagation and clonal evolution of lymphoma.”

Manoela Tiago dos Santos, Ph.D.

Thomas Jefferson University, Philadelphia, PA

PROJECT:  BET inhibition to optimize BRAFi/MEKi therapy for mutant BRAF
“BRAF+MEK inhibitors (BRAFi/MEKi) have great but short response in BRAF-mutant melanoma patients. Failure of treatment is due to drug-tolerant tumor cells that lead to disease progression. We tested the effect of an epigenetic inhibitor, PLX51107, on enhancing BRAFi/MEKi outcomes. PLX51107 improved the duration of responses following BRAFi/MEKi treatment in tumor cells and animal studies.”

Yuanfan Yang, M.D.

Duke Univ Medical Center, Durham, NC

PROJECT: Anti-tumor efficacy of EGFR-targeting immunotoxin in combination with CCNU or PD-L1 blockade in glioma mouse models
“I am studying how brain cancers take advantage of their niche to evade attack from promising immunotherapies, and to tackle their tricks.”

Yuanyuan Li, Ph.D.

Icahn School of Medicine at Mt Sinai

PROJECT: IRAK1 Kinase drives cell survival in response to ionizing radiation and defines a target to overcome intrinsic tumor radioresistance
“Inhibition of IRAK1 kinase activity overcomes resistance to radiation therapy in human cancer. Dissection of the mechanism by which IRAK1 senses IR-induced cellular damage and the pathways through which it prevents radiation-induced apoptosis.”

Siva Karthik Varanasi, Ph.D.

Salk Inst for Biological Studies

PROJECT: Evaluating the role of bile acids as a metabolic checkpoint of anti-tumor T cell Hepatocellular Carcinoma
“The project is aimed at understanding how bile acids that accumulate within liver tumors suppress the anti-tumor immune responses of T cells.”

Yuanyuan Xie, Ph.D.

Regents of the Univ of Colorado

PROJECT: Elucidating the functional and genomic impact of retrocopies on cancer
“Elucidating the functional and genomic impact of retrocopies on cancer, which are RNA-mediated duplicated DNAs that are often assumed nonfunctional, but become widely expressed in tumors.”

Joy Bianchi, Ph.D.

NYU Langone Health

PROJECT: Targeting copy number alterations to overcome immune evasion in melanoma
“I am interested in identifying new biomarkers to predict melanoma patients’ response to immunotherapy by studying the relationship between the capacity of tumor cells to escape our immune system and chromosomal abnormalities in cancer.”

Ulrike Gerdemann, M.D.

Dana-Farber Cancer Institute

PROJECT: Improving function and persistence of CAR T-cells
“The project focuses on improving potency and longevity of CAR T cell therapeutics to prevent relapse and extend the application of this new therapy from leukemias to solid tumors.”

Haopeng Xiao, Ph.D.

Dana-Farber Cancer Institute

PROJECT: Proteomic approaches to investigate Redox control in cancer
“In this proposal, a proteomic strategy will be developed to identify cysteine signaling sites of reactive oxygen species that play crucial cancer-driving versus cancer-inhibiting roles.”

Siang-Boon Koh, Ph.D.

Massachusetts General Hospital Cancer Center

PROJECT: Synergistic targeting of DNA damage response and EMT pathways to reverse RASAL2-driven chemoresistance
“I am studying the mechanisms of treatment resistance in aggressive breast cancer, with the goal to devise more effective and rational therapies against these tumors.”